Global Opioid Induced Constipation (OIC) Drugs Market Research Report 2026(Status and Outlook)
Description
Report Overview
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Opioid Induced Constipation (OIC) Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.Opioid Induced Constipation (OIC) refers to constipation symptoms induced by the prolonged use of opioid analgesics such as morphine, fentanyl, and oxycodone. This side effect is particularly common among chronic pain patients and significantly impacts their quality of life. To address this issue, various OIC drugs have been developed, including peripheral µ-opioid receptor antagonists (PAMORAs), prokinetic agents, osmotic or bulk-forming laxatives, stimulant laxatives, and combination therapies. These drugs alleviate or treat constipation symptoms caused by opioid use through different mechanisms of action.In 2024, global Opioid Induced Constipation (OIC) Drugs production reached approximately 277.5 m units , with an average global market price of around US$ 10 perunit.The average gross profit margin of this product is 37%.The accelerating global aging process and the increasing number of chronic disease patients, especially cancer patients and those undergoing long-term analgesic treatment, have led to a rise in opioid use, thereby increasing the incidence of OIC. Moreover, the growing attention of medical institutions to patients' quality of life has driven the demand for OIC treatment drugs. The development and launch of new drugs, such as Naldemedine, have introduced new treatment options to the market, further promoting its development.Despite the growing market demand, the high cost of OIC drugs remains a major challenge for patients and healthcare systems. Additionally, some drugs may have side effects, such as diarrhea and nausea, affecting patient compliance. In certain regions, especially in China, treatment options for OIC are limited, primarily relying on adjusting opioid doses or using traditional laxatives, which restricts further market development.As patients place more emphasis on quality of life, medical institutions' awareness of OIC has increased, driving the use of OIC drugs. Particularly in cancer treatment and chronic pain management, the demand for OIC drugs continues to grow. Furthermore, the increasing demand for personalized treatment has driven the research and application of OIC drugs tailored to different patient groups.The production of OIC drugs involves various raw materials, including active pharmaceutical ingredients (APIs), excipients, and packaging materials. The production of APIs requires high-purity chemical raw materials and complex synthesis processes to ensure the efficacy and safety of the drugs. Excipients, such as fillers and stabilizers, influence the stability of the drugs and the patient's experience. The choice of packaging materials relates to the storage and transportation conditions of the drugs. Therefore, the quality and supply stability of raw materials are crucial to the production of OIC drugs.
The global Opioid Induced Constipation (OIC) Drugs market size was estimated at USD 2775.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 4.60% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Opioid Induced Constipation (OIC) Drugs market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Opioid Induced Constipation (OIC) Drugs market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Opioid Induced Constipation (OIC) Drugs market.
Global Opioid Induced Constipation (OIC) Drugs Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Bausch Health
Zentiva
Orifarm A/S
Viatris
Endo International
Zhengdatianqing
Market Segmentation (by Type)
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Market Segmentation (by Application)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Opioid Induced Constipation (OIC) Drugs Market
Overview of the regional outlook of the Opioid Induced Constipation (OIC) Drugs Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Opioid Induced Constipation (OIC) Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Opioid Induced Constipation (OIC) Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Opioid Induced Constipation (OIC) Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.Opioid Induced Constipation (OIC) refers to constipation symptoms induced by the prolonged use of opioid analgesics such as morphine, fentanyl, and oxycodone. This side effect is particularly common among chronic pain patients and significantly impacts their quality of life. To address this issue, various OIC drugs have been developed, including peripheral µ-opioid receptor antagonists (PAMORAs), prokinetic agents, osmotic or bulk-forming laxatives, stimulant laxatives, and combination therapies. These drugs alleviate or treat constipation symptoms caused by opioid use through different mechanisms of action.In 2024, global Opioid Induced Constipation (OIC) Drugs production reached approximately 277.5 m units , with an average global market price of around US$ 10 perunit.The average gross profit margin of this product is 37%.The accelerating global aging process and the increasing number of chronic disease patients, especially cancer patients and those undergoing long-term analgesic treatment, have led to a rise in opioid use, thereby increasing the incidence of OIC. Moreover, the growing attention of medical institutions to patients' quality of life has driven the demand for OIC treatment drugs. The development and launch of new drugs, such as Naldemedine, have introduced new treatment options to the market, further promoting its development.Despite the growing market demand, the high cost of OIC drugs remains a major challenge for patients and healthcare systems. Additionally, some drugs may have side effects, such as diarrhea and nausea, affecting patient compliance. In certain regions, especially in China, treatment options for OIC are limited, primarily relying on adjusting opioid doses or using traditional laxatives, which restricts further market development.As patients place more emphasis on quality of life, medical institutions' awareness of OIC has increased, driving the use of OIC drugs. Particularly in cancer treatment and chronic pain management, the demand for OIC drugs continues to grow. Furthermore, the increasing demand for personalized treatment has driven the research and application of OIC drugs tailored to different patient groups.The production of OIC drugs involves various raw materials, including active pharmaceutical ingredients (APIs), excipients, and packaging materials. The production of APIs requires high-purity chemical raw materials and complex synthesis processes to ensure the efficacy and safety of the drugs. Excipients, such as fillers and stabilizers, influence the stability of the drugs and the patient's experience. The choice of packaging materials relates to the storage and transportation conditions of the drugs. Therefore, the quality and supply stability of raw materials are crucial to the production of OIC drugs.
The global Opioid Induced Constipation (OIC) Drugs market size was estimated at USD 2775.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 4.60% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Opioid Induced Constipation (OIC) Drugs market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Opioid Induced Constipation (OIC) Drugs market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Opioid Induced Constipation (OIC) Drugs market.
Global Opioid Induced Constipation (OIC) Drugs Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Bausch Health
Zentiva
Orifarm A/S
Viatris
Endo International
Zhengdatianqing
Market Segmentation (by Type)
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Market Segmentation (by Application)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Opioid Induced Constipation (OIC) Drugs Market
Overview of the regional outlook of the Opioid Induced Constipation (OIC) Drugs Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Opioid Induced Constipation (OIC) Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Opioid Induced Constipation (OIC) Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Table of Contents
170 Pages
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Opioid Induced Constipation (OIC) Drugs
- 1.2 Key Market Segments
- 1.2.1 Opioid Induced Constipation (OIC) Drugs Segment by Type
- 1.2.2 Opioid Induced Constipation (OIC) Drugs Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Opioid Induced Constipation (OIC) Drugs Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Opioid Induced Constipation (OIC) Drugs Market Size (M USD) Estimates and Forecasts (2020-2035)
- 2.1.2 Global Opioid Induced Constipation (OIC) Drugs Sales Estimates and Forecasts (2020-2035)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 Opioid Induced Constipation (OIC) Drugs Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Opioid Induced Constipation (OIC) Drugs Product Life Cycle
- 3.3 Global Opioid Induced Constipation (OIC) Drugs Sales by Manufacturers (2020-2025)
- 3.4 Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Opioid Induced Constipation (OIC) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Opioid Induced Constipation (OIC) Drugs Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Opioid Induced Constipation (OIC) Drugs Market Competitive Situation and Trends
- 3.8.1 Opioid Induced Constipation (OIC) Drugs Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Opioid Induced Constipation (OIC) Drugs Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Opioid Induced Constipation (OIC) Drugs Industry Chain Analysis
- 4.1 Opioid Induced Constipation (OIC) Drugs Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Opioid Induced Constipation (OIC) Drugs Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Opioid Induced Constipation (OIC) Drugs Market Porter's Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Opioid Induced Constipation (OIC) Drugs Market
- 5.7 ESG Ratings of Leading Companies
- 6 Opioid Induced Constipation (OIC) Drugs Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Type (2020-2025)
- 6.3 Global Opioid Induced Constipation (OIC) Drugs Market Size by Type (2020-2025)
- 6.4 Global Opioid Induced Constipation (OIC) Drugs Price by Type (2020-2025)
- 7 Opioid Induced Constipation (OIC) Drugs Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Opioid Induced Constipation (OIC) Drugs Market Sales by Application (2020-2025)
- 7.3 Global Opioid Induced Constipation (OIC) Drugs Market Size (M USD) by Application (2020-2025)
- 7.4 Global Opioid Induced Constipation (OIC) Drugs Sales Growth Rate by Application (2020-2025)
- 8 Opioid Induced Constipation (OIC) Drugs Market Sales by Region
- 8.1 Global Opioid Induced Constipation (OIC) Drugs Sales by Region
- 8.1.1 Global Opioid Induced Constipation (OIC) Drugs Sales by Region
- 8.1.2 Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Region
- 8.2 Global Opioid Induced Constipation (OIC) Drugs Market Size by Region
- 8.2.1 Global Opioid Induced Constipation (OIC) Drugs Market Size by Region
- 8.2.2 Global Opioid Induced Constipation (OIC) Drugs Market Size by Region
- 8.3 North America
- 8.3.1 North America Opioid Induced Constipation (OIC) Drugs Sales by Country
- 8.3.2 North America Opioid Induced Constipation (OIC) Drugs Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Opioid Induced Constipation (OIC) Drugs Sales by Country
- 8.4.2 Europe Opioid Induced Constipation (OIC) Drugs Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Opioid Induced Constipation (OIC) Drugs Sales by Region
- 8.5.2 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Opioid Induced Constipation (OIC) Drugs Sales by Country
- 8.6.2 South America Opioid Induced Constipation (OIC) Drugs Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Opioid Induced Constipation (OIC) Drugs Sales by Region
- 8.7.2 Middle East and Africa Opioid Induced Constipation (OIC) Drugs Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 9 Opioid Induced Constipation (OIC) Drugs Market Production by Region
- 9.1 Global Production of Opioid Induced Constipation (OIC) Drugs by Region(2020-2025)
- 9.2 Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Region (2020-2025)
- 9.3 Global Opioid Induced Constipation (OIC) Drugs Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Opioid Induced Constipation (OIC) Drugs Production
- 9.4.1 North America Opioid Induced Constipation (OIC) Drugs Production Growth Rate (2020-2025)
- 9.4.2 North America Opioid Induced Constipation (OIC) Drugs Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Opioid Induced Constipation (OIC) Drugs Production
- 9.5.1 Europe Opioid Induced Constipation (OIC) Drugs Production Growth Rate (2020-2025)
- 9.5.2 Europe Opioid Induced Constipation (OIC) Drugs Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Opioid Induced Constipation (OIC) Drugs Production (2020-2025)
- 9.6.1 Japan Opioid Induced Constipation (OIC) Drugs Production Growth Rate (2020-2025)
- 9.6.2 Japan Opioid Induced Constipation (OIC) Drugs Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Opioid Induced Constipation (OIC) Drugs Production (2020-2025)
- 9.7.1 China Opioid Induced Constipation (OIC) Drugs Production Growth Rate (2020-2025)
- 9.7.2 China Opioid Induced Constipation (OIC) Drugs Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 Takeda Pharmaceuticals
- 10.1.1 Takeda Pharmaceuticals Basic Information
- 10.1.2 Takeda Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.1.3 Takeda Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.1.4 Takeda Pharmaceuticals Business Overview
- 10.1.5 Takeda Pharmaceuticals SWOT Analysis
- 10.1.6 Takeda Pharmaceuticals Recent Developments
- 10.2 Bayer
- 10.2.1 Bayer Basic Information
- 10.2.2 Bayer Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.2.3 Bayer Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.2.4 Bayer Business Overview
- 10.2.5 Bayer SWOT Analysis
- 10.2.6 Bayer Recent Developments
- 10.3 Sanofi
- 10.3.1 Sanofi Basic Information
- 10.3.2 Sanofi Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.3.3 Sanofi Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.3.4 Sanofi Business Overview
- 10.3.5 Sanofi SWOT Analysis
- 10.3.6 Sanofi Recent Developments
- 10.4 Mallinckrodt
- 10.4.1 Mallinckrodt Basic Information
- 10.4.2 Mallinckrodt Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.4.3 Mallinckrodt Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.4.4 Mallinckrodt Business Overview
- 10.4.5 Mallinckrodt Recent Developments
- 10.5 Salix (Bausch Health)
- 10.5.1 Salix (Bausch Health) Basic Information
- 10.5.2 Salix (Bausch Health) Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.5.3 Salix (Bausch Health) Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.5.4 Salix (Bausch Health) Business Overview
- 10.5.5 Salix (Bausch Health) Recent Developments
- 10.6 AstraZeneca
- 10.6.1 AstraZeneca Basic Information
- 10.6.2 AstraZeneca Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.6.3 AstraZeneca Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.6.4 AstraZeneca Business Overview
- 10.6.5 AstraZeneca Recent Developments
- 10.7 Progenics Pharmaceuticals
- 10.7.1 Progenics Pharmaceuticals Basic Information
- 10.7.2 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.7.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.7.4 Progenics Pharmaceuticals Business Overview
- 10.7.5 Progenics Pharmaceuticals Recent Developments
- 10.8 Purdue Pharm
- 10.8.1 Purdue Pharm Basic Information
- 10.8.2 Purdue Pharm Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.8.3 Purdue Pharm Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.8.4 Purdue Pharm Business Overview
- 10.8.5 Purdue Pharm Recent Developments
- 10.9 Nektar Therapeutics
- 10.9.1 Nektar Therapeutics Basic Information
- 10.9.2 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.9.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.9.4 Nektar Therapeutics Business Overview
- 10.9.5 Nektar Therapeutics Recent Developments
- 10.10 Daiichi Sankyo
- 10.10.1 Daiichi Sankyo Basic Information
- 10.10.2 Daiichi Sankyo Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.10.3 Daiichi Sankyo Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.10.4 Daiichi Sankyo Business Overview
- 10.10.5 Daiichi Sankyo Recent Developments
- 10.11 Prestige
- 10.11.1 Prestige Basic Information
- 10.11.2 Prestige Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.11.3 Prestige Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.11.4 Prestige Business Overview
- 10.11.5 Prestige Recent Developments
- 10.12 GSK
- 10.12.1 GSK Basic Information
- 10.12.2 GSK Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.12.3 GSK Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.12.4 GSK Business Overview
- 10.12.5 GSK Recent Developments
- 10.13 Shionogi
- 10.13.1 Shionogi Basic Information
- 10.13.2 Shionogi Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.13.3 Shionogi Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.13.4 Shionogi Business Overview
- 10.13.5 Shionogi Recent Developments
- 10.14 Bausch Health
- 10.14.1 Bausch Health Basic Information
- 10.14.2 Bausch Health Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.14.3 Bausch Health Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.14.4 Bausch Health Business Overview
- 10.14.5 Bausch Health Recent Developments
- 10.15 Zentiva
- 10.15.1 Zentiva Basic Information
- 10.15.2 Zentiva Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.15.3 Zentiva Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.15.4 Zentiva Business Overview
- 10.15.5 Zentiva Recent Developments
- 10.16 Orifarm A/S
- 10.16.1 Orifarm A/S Basic Information
- 10.16.2 Orifarm A/S Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.16.3 Orifarm A/S Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.16.4 Orifarm A/S Business Overview
- 10.16.5 Orifarm A/S Recent Developments
- 10.17 Viatris
- 10.17.1 Viatris Basic Information
- 10.17.2 Viatris Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.17.3 Viatris Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.17.4 Viatris Business Overview
- 10.17.5 Viatris Recent Developments
- 10.18 Endo International
- 10.18.1 Endo International Basic Information
- 10.18.2 Endo International Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.18.3 Endo International Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.18.4 Endo International Business Overview
- 10.18.5 Endo International Recent Developments
- 10.19 Zhengdatianqing
- 10.19.1 Zhengdatianqing Basic Information
- 10.19.2 Zhengdatianqing Opioid Induced Constipation (OIC) Drugs Product Overview
- 10.19.3 Zhengdatianqing Opioid Induced Constipation (OIC) Drugs Product Market Performance
- 10.19.4 Zhengdatianqing Business Overview
- 10.19.5 Zhengdatianqing Recent Developments
- 11 Opioid Induced Constipation (OIC) Drugs Market Forecast by Region
- 11.1 Global Opioid Induced Constipation (OIC) Drugs Market Size Forecast
- 11.2 Global Opioid Induced Constipation (OIC) Drugs Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Opioid Induced Constipation (OIC) Drugs Market Size Forecast by Country
- 11.2.3 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Size Forecast by Region
- 11.2.4 South America Opioid Induced Constipation (OIC) Drugs Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Opioid Induced Constipation (OIC) Drugs by Country
- 12 Forecast Market by Type and by Application (2026-2035)
- 12.1 Global Opioid Induced Constipation (OIC) Drugs Market Forecast by Type (2026-2035)
- 12.1.1 Global Forecasted Sales of Opioid Induced Constipation (OIC) Drugs by Type (2026-2035)
- 12.1.2 Global Opioid Induced Constipation (OIC) Drugs Market Size Forecast by Type (2026-2035)
- 12.1.3 Global Forecasted Price of Opioid Induced Constipation (OIC) Drugs by Type (2026-2035)
- 12.2 Global Opioid Induced Constipation (OIC) Drugs Market Forecast by Application (2026-2035)
- 12.2.1 Global Opioid Induced Constipation (OIC) Drugs Sales (K MT) Forecast by Application
- 12.2.2 Global Opioid Induced Constipation (OIC) Drugs Market Size (M USD) Forecast by Application (2026-2035)
- 13 Conclusion and Key Findings
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
